Insider buying · SEC Form 4

Insider Buying — Aug 20, 2026

Company insiders — CEOs, CFOs, directors and 10% owners — buying their own company's stock on the open market: every purchase of $250K or more from the previous day's Form 4 filings, largest first, with an AI summary of the day.

7insider buys
$18.7Mbought in total
6companies
3by CEOs, CFOs and other chiefs
ZNTLlargest: $15.2M

Every qualifying buy, largest first

StockInsiderValueSharesAvg priceTypeFiled
ZNTLZentalis Pharmaceuticals, Inc.The Walters Group (William T. Walters, Susan B. Walters)10% Owner$15.2M4,335,000$3.50AddedAug 19, 2026
Form 4 ↗
4,335,000 shares at $3.50 avg (traded Aug 14); now $3.82 (+9.1% since buy). Raises total ZNTL stake to ~17.8M shares. Clinical-stage oncology deep-value thesis.
AATAmerican Assets Trust, Inc.Ernest S. RadyExecutive Chairman, 10% Owner$1.44M63,586$22.59AddedAug 19, 2026
Form 4 ↗
63,586 shares at $22.60 weighted avg across Aug 17–19 (50K at $22.55 / 3,586 at $22.69 / 10K at $22.77); now $22.80 (+0.9%). Founder-chairman three-day accumulation at multi-year lows.
LIENChicago Atlantic BDC, Inc.John Mazarakis10% Owner$566K60,000$9.44AddedAug 19, 2026
Form 4 ↗
60,000 shares at $9.44 weighted avg (range $9.39–$9.44) on Aug 17; now $9.50 (+0.6%). Cluster buy: bought alongside Co-CIO Gordon Scott ($421K) and also bought REFI the same day.
MFPMidera Food Processing, Inc.Robert A. NerbonneDirector$491K10,900$45.05AddedAug 19, 2026
Form 4 ↗
10,900 shares at $45.05 on Aug 17; now $45.71 (+1.5%). Midera is a recent Middleby Corp spinoff (commercial food equipment). Nerbonne is a former food-service CEO with sector expertise.
LIENChicago Atlantic BDC, Inc.Gordon ScottDirector, Co-Chief Investment Officer$421K44,084$9.55AddedAug 19, 2026
Form 4 ↗
44,084 shares across Aug 17–19: 18,300 at $9.54 / 17,584 at $9.54 / 8,200 at $9.57; now $9.50 (-0.4%). Bought in parallel with Mazarakis — two senior insiders accumulating LIEN concurrently.
DGICADonegal Group, Inc.Donegal Mutual Insurance Co10% Owner$371K20,000$18.56AddedAug 19, 2026
Form 4 ↗
20,000 Class A shares on Aug 17–18 (10K at $18.5239 / 10K at $18.5955); now $18.51 (-0.2%). Parent insurer steady accumulation of its publicly traded affiliate; existing position >14M shares.
REFIChicago Atlantic Real Estate Finance, Inc.John MazarakisChairman$256K25,000$10.25AddedAug 19, 2026
Form 4 ↗
25,000 shares at $10.25 on Aug 17; now $10.59 (+3.3%). Bought shortly after REFI missed consensus EPS by $0.05 — post-earnings conviction buy. Mazarakis simultaneously bought LIEN (~$566K).

AIThe day in insider buying

SEC Form 4 Insider Scan — August 20, 2026

Scanned the last 24 hours of EDGAR Form 4 filings. 7 qualifying buys (≥ $250K, transaction type P) totalling $18.7M.

Headline filings

  • ZNTL — The Walters Group (10% Owner) bought 4,335,000 shares ≈ $15.2M at $3.50 avg (traded Aug 14, filed Aug 19); now $3.82 (+9.1% since buy). Largest buy of the session by a wide margin — raises their total ZNTL stake to ~17.8M shares. (filing)
  • AAT — Ernest S. Rady (Executive Chairman, 10% Owner) bought 63,586 shares ≈ $1.4M at $22.60 weighted avg across Aug 17–19; now $22.80 (+0.9% since buy). Three-day accumulation by the REIT's founder-chairman. (filing)
  • LIEN — John Mazarakis (10% Owner) bought 60,000 shares ≈ $566K at $9.44 avg on Aug 17; now $9.50 (+0.6%). Part of a Chicago Atlantic cluster buy — Co-CIO Gordon Scott also bought 44,084 shares ($421K) across Aug 17–19. (filing)
  • MFP — Robert A. Nerbonne (Director) bought 10,900 shares ≈ $491K at $45.05 on Aug 17; now $45.71 (+1.5%). Midera Food Processing is a recent Middleby spinoff; Nerbonne is a former commercial food-equipment CEO adding to his position. (filing)
  • LIEN — Gordon Scott (Director, Co-CIO) bought 44,084 shares ≈ $421K at $9.54 avg across Aug 17–19; now $9.50 (-0.4% since buy). Bought alongside Mazarakis — two senior Chicago Atlantic BDC insiders accumulating in the same window. (filing)
  • DGICA — Donegal Mutual Insurance Co (10% Owner) bought 20,000 Class A shares ≈ $371K at $18.52–18.60 on Aug 17–18; now $18.51 (-0.2%). Parent insurer continuing its steady accumulation of its publicly traded affiliate. (filing)
  • REFI — John Mazarakis (Chairman) bought 25,000 shares ≈ $256K at $10.25 on Aug 17; now $10.59 (+3.3% since buy). Bought shortly after REFI missed consensus EPS by $0.05 — a conviction buy post-earnings. Mazarakis bought both REFI and LIEN in the same window. (filing)

Notes

Chicago Atlantic cluster: John Mazarakis (10% owner / Chairman), Gordon Scott (Director / Co-CIO), and Fazio (CAO, token buy) all bought LIEN shares on Aug 17–19, while Mazarakis simultaneously added REFI. Combined Chicago Atlantic-platform buying (LIEN + REFI) totals ~$1.24M across two principal buyers — a strong coordinated conviction signal for the Chicago Atlantic credit BDC.

ZNTL mega-buy: The Walters Group's $15.2M purchase of Zentalis Pharmaceuticals at $3.50 dominates the scan. At +9.1% since entry, the Walters are already in the green. Zentalis is a clinical-stage oncology company; this appears to be a deep-value thesis purchase of a beaten-down biotech.

AAT founder buying: Ernest Rady's $1.4M three-day accumulation in American Assets Trust adds to his already-substantial founder stake. AAT is a diversified REIT trading near multi-year lows.

Themes: Credit BDCs / real estate (AAT, LIEN, REFI) and biotech (ZNTL) dominate buy-side activity. A single mega-buyer (ZNTL) skews the total; ex-ZNTL, the remaining 6 buys total ~$3.5M across real estate, credit, insurance, and food processing.

Most-bought stocks, last 30 days

  • SCTX $56.3M · 3 buys, 3 insidersScribe Therapeutics Inc.
  • COE $47.7M · 6 buys, 2 insiders51Talk Online Education Group
  • MPLT $15.3M · 1 buyMapLight Therapeutics, Inc.
  • ZNTL $15.2M · 1 buyZentalis Pharmaceuticals, Inc.
  • FLUT $11.8M · 1 buyFlutter Entertainment plc
  • LBRX $10.0M · 1 buyLB Pharmaceuticals Inc.
  • BSX $9.00M · 1 buyBoston Scientific Corp
  • ONON $7.98M · 4 buys, 3 insidersOn Holding AG
  • PBLS $6.92M · 1 buyParabilis Medicines, Inc.
  • APMD $5.00M · 1 buyApnimed, Inc.
  • BLSM $5.00M · 1 buyBlossomHill Therapeutics, Inc.
  • GSHD $4.49M · 3 buysGoosehead Insurance, Inc.
  • BORR $4.39M · 2 buysBorr Drilling Ltd
  • TXO $3.58M · 2 buysTXO Partners, L.P.
  • LILA $2.90M · 1 buyLiberty Latin America Ltd.
  • ARTV $2.58M · 1 buyArtiva Biotherapeutics, Inc.
  • LTGO $2.52M · 1 buyLatigo Biotherapeutics, Inc.
  • APTV $2.50M · 1 buyAptiv PLC
  • CSGP $2.49M · 1 buyCoStar Group, Inc.
  • ACI $2.41M · 2 buys, 2 insidersAlbertsons Companies, Inc.

All scans

Source: insiders' SEC Form 4 filings — open-market purchases (transaction code P) of $250K or more filed in the previous day. Insiders must file within two business days of a trade, so a purchase can be a day or two older than its filing. Average price = value ÷ shares. Insiders buy for many reasons and a purchase is no guarantee the shares will rise. The summaries are written by AI as a research aid — not financial advice or a recommendation to buy or sell any security, and they can be wrong.

SPX Lens Insider Buying reads the SEC Form 4 filings insiders file after trading their own company's stock and lists every open-market purchase of $250K or more — who bought, their role, how much and at what average price. Insiders sell for many reasons, but they usually buy for one: they think the shares are worth more. It is free, and a new scan is posted every trading day. How to read insider buying →

See where SPX is heading next. The SPX Lens chart shows key levels, live signals and an AI forecast for the next bars — free to try.

Open the live chartOpen in the Stocks tab

© SPX Lens · About · Terms · Privacy — for educational purposes only, not financial advice.